PT-141 SPRAY
$59.99
A 7-amino acid cyclic peptide analog of alpha-MSH that activates melanocortin receptors MC3R and MC4R, FDA-approved for hypoactive sexual desire disorder and studied for sexual function in clinical research. Premium Research Peptide.
1000 in stock
🔥 Exclusive Crypto Offer
Get an INSTANT 15% DISCOUNT when you pay with Bitcoin, Ethereum, Dogecoin, Bitcoin Cash, XRP, Solana, or USDT.
âš¡ Don't have crypto? Buy it here in 5 minutes with easy guidance.
💡 Pro Tip: You can also pay with cryptocurrency using your verified Cash App or PayPal account for a fast and secure checkout!
Certificate of Analysis
Third Party Tested • ISO/IEC 17025 Accredited • Premium Quality
Purity: 99.62% (✓ Passed Full QC Panel)
PT-141 10mg Specification
| Variant | PT-141 10mg |
| Lot # | PT0001 |
| Labeled | 10mg |
| Actual | 10.61mg |
| Tested | May 29, 2026 |
| Full QC Panel | 7× tested |
| Purity (HPLC) | 99.62% |
| Net Peptide Content | 10.61mg |
| Identity (HPLC) | PT-141 |
| HPLC Conformity | mean 99.59% |
| Heavy Metals (ICP-MS) | Not Detected |
| Sterility (PCR) | No Growth |
| Endotoxin (USP <85>) | < 0.05 EU/mLISO/IEC 17025 Accredited |
Frequently Researched Together
Melanocortin receptor research compounds
Molecular Profile
What Is PT-141?
Cyclic heptapeptide analog of alpha-MSH, active metabolite of Melanotan II
| Cyclic Peptide | |
| FDA Approved | |
| Type | Cyclic heptapeptide |
| CAS Number | 189691-06-3 |
| Molecular Formula | C50H68N14O10 |
| Molecular Weight | 1025.2 g/mol |
| Amino Acids | 7 residues |
| Sequence | Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| PubChem Database | |
Physical Properties
Handling & Storage
Supplied ready to use. No reconstitution required.
| Ready to use | |
| Protect from direct light | |
| Appearance | Clear, colorless solution |
| Diluent | Antimicrobial preserved water |
| Storage | 34°F to 120°F (1°C to 49°C) |
| Shelf life | Up to 8 months |
Development Status
Regulatory Information
Developed by Palatin Technologies, approved by FDA
| Developer | Palatin Technologies |
| Marketing | AMAG Pharmaceuticals |
| FDA Approval | June 21, 2019 |
| Trade Name | Vyleesi |
| Indication | HSDD in premenopausal women |
| Male Use | Not approved (research only) |
| FDA Approval Letter | |
